BioWorld

June 30, 2003

GSK Spin-Off Affymax Generates $20M In Private Financing Round

Affymax Inc. closed a $20 million private round of financing that coincided with the drug discovery and development firm's appointment of a new chief executive. (BioWorld Today) Read More

CBER, CDER Consolidation Plan Goes Into Effect Today

To Detect Infectious Pathogens In Body, Pasteur Scientists Unravel Adaptive Immunity From Innate

Inex 'Bought-Deal' Agreement To Raise $18.6M For Pipeline

Labopharm Raising C$22M As It Nears Tramadol Application

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...